The use of PI3K and AKT inhibitors in combination with chemotherapy, endocrine therapy, HER2-targeted therapies, cyclin-dependent kinase 4/6 (CDK4/6) and poly ADP ribose polymerase (PARP) inhibitors, has been explored in pre-clinical and clinical models across multiple tumor types (13–27). This evidence concerns the gene PIK3CA and neoplasm.